



Docket No.: 60841(50530)

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Zhenwei Miao et al

Application No.: 10/774,047 Confirmation No : 4991

Filed: February 6, 2004 Art Unit: N/A

For: MACROCYCLIC HEPATITIS C SERINE

Examiner: Not Yet Assigned PROTEASE INHIBITORS

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each non-US patent reference on the PTO/SB/08 are attached.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Docket No.: 60841(50530)

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 60841(50530). A duplicate copy of this paper is enclosed.

Dated: 10 June 2005

Respectfully submitted,

Jeffrey D. Hsi

Registration No.: 40,024 EDWARDS & ANGELL, LLP

P.O. Box 55874 Boston, Massachusetts 02205 (617) 439-4444 Attorneys/Agents For Applicant BOS2_493886.1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV438976459US in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Signature Reen

Typed or printed name of person signing Certificate

(617) 439-4444

Registration Number, if applicable

Registration Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (9 References) (1 page) Information Disclosure Statement (2 pages)

JUN 1 0 2005 5

Sheet

PTO/SB06a/b (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTIMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/B/PTO

 Complete if Known

 Application Number
 10/774,047-Conf. #4991

 Filling Date
 February 6, 2004

 First Named Inventor
 Zhenwei Miao

 Art Unit
 N/A

 Examiner Name
 Not Yet Assigned

60841(50530)

(Use as many sheets as necessary)

1 of 1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/N.J.		6,608,027	8-19-2003	Tsantrizos et al.	
\/		US 2002/0037998 A1	3-28-02	Llinas-Brunet et al.	
V		6,329,379	12-2001	Llinas-Brunet et al.	

8-19-2003

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
/N.J.	ВА	WO-00/09543	02-24-2000	Boehringer Ingelheim (Canada) Ltd.		П
	ВВ	WO-00/59929	10-12-2000	Boehringer Ingelheim (Canada) Ltd.		
N/	BC	WO-2003/053349-A3	07-03-2003	Bristol-Myers Squibb		
V	BD	WO-2004/072243-A2	08-26-2004	Enanta Pharmaceuticals, Inc.		\Box

"EXAMINE: Initial if ofference consistents, whether or not claims is in conformance with MBEP 809. Draw fire through classion if not in proformance and not consistent, include copy of this form with meat communication payageant." Appears in unique classion exispation in number (optional). "See Kinds Codes or USPTO Pears in December 2019, "For a consistent in the communication of the C

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
/N.J./	CA	A. Spatola, "Peptide Backbone Modifications: A Structure-Activity Analysis of Peptides Containing Amide Bond Surrogates, Conformational Constraints, and Rela," Department of Chemistry, University of Louisville, Louisville Kentucky, pp. 267-357, XP 020232461.1 982		
/N.J./	СВ	M. Llinas-Brunet, et al., "Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease," Bioorganic & Medicinal Chemistry Letters 8, (1998), pp. 1713-1718.		

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

BOS2_493887.1

Examiner Signature	/Noble Jarrell/	Date Considered	07/03/2007